Skip to main content
Erschienen in: BMC Cancer 1/2020

Open Access 01.12.2020 | Research article

Tissue mechanics and expression of TROP2 in oral squamous cell carcinoma with varying differentiation

verfasst von: Baoping Zhang, Shuting Gao, Ruiping Li, Yiting Li, Rui Cao, Jingyang Cheng, Yumeng Guo, Errui Wang, Ying Huang, Kailiang Zhang

Erschienen in: BMC Cancer | Ausgabe 1/2020

Abstract

Background

Trophoblast cell surface antigen 2 (TROP2) is overexpressed in many squamous cell carcinomas and promotes tumor development and invasion. The association between TROP2 expression and occurrence and development of oral squamous cell carcinoma (OSCC) remains to be understood.

Methods

We investigated the role of TROP2 in OSCC patients using a combination of biophysical approaches. A total of 108 OSCC patient specimens with varying degrees of differentiation were subjected to hematoxylin and eosin staining, immunohistochemistry, Kaplan-Meier survival curve analysis, and atomic force microscopy to analyze TROP2 expression, morphology, and mechanical properties of OSCC tissues.

Results

TROP2 was overexpressed in 34% of poorly differentiated OSCC samples. High levels of TROP2 were associated with 10.2% survival rate lower than 45.4% and patient age (odds ratio [OR] = 0.437, P = 0.039, 95% confidence interval [CI, 0.198–0.966]), tumor size (OR = 13.148, P = 0.000, 95% CI [5.060–34.168]), and TNM stage (OR = 0.141, P = 0.000, 95% CI [0.082–0.244]). Average surface roughness of low, medium, and highly differentiated OSCC tissues were 448.9 ± 54.8, 792.7 ± 83.6, and 993.0 ± 104.3 nm, respectively. The Pearson coefficient revealed a negative association between tumor stiffness and TROP2 expression (r = − 0.84, P < 0.01).

Conclusion

Overexpression of TROP2 negatively associated with patient survival, degree of tumor differentiation, and tissue mechanics. Taken together, our findings demonstrated that TROP2 may be an indicator of OSCC differentiation leading to the altered mechanical properties of OSCC tissues.
Hinweise
Baoping Zhang, Shuting Gao and Ruiping Li contributed equally to this work.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
OSCC
Oral squamous cell carcinoma
TROP2
Trophoblast cell surface antigen 2
AFM
Atomic force microscopy

Background

Oral squamous cell carcinoma (OSCC) is a common subtype of head and neck and other malignant tumors [1, 2]. The past few decades have shown increased incidence of OSCC that is expected to rise further in the future [3]. Therefore, it is imperative to determine biological factors associated with the early diagnosis and treatment of OSCC.
Human trophoblast cell surface antigen 2 (TROP2), also called tumor-associated calcium signal transduction-2 (TACSTD-2), is a surface glycoprotein encoded by TACSTD that has extracellular domains, a single transmembrane domain, and a short tail [4, 5]. TROP2 is overexpressed in many human cancers, including ovarian [6, 7], gastric [8, 9], colorectal [10], pancreatic [11], and laryngeal cancers [12]. Inhibiting TROP2 expression has shown promise in clinical applications [13, 14]. TROP2 regulates tumorigenic properties including cancer cell adhesion, invasion, and migration. Tang et al. [15] have recently shown that TROP2 impacts growth and metastasis by activating PI3K/AKT signaling. This phenomenon has also been observed in gallbladder cancer [16]. Among the various biochemical mechanisms involved in tumorigenesis, the role of β-catenin has been studied extensively [8, 1719]. This has shed light on the biological functions of TROP2 and its use as a prognostic biomarker for OSCC.
Atomic force microscopy (AFM) is a powerful tool that generates surface topographical images with magnifications that range between macro- and nanoscales. AFM has been used to determine the mechanical properties of tumor tissues in a variety of cancers, such as those of the breast [20], liver [21], and lung [22]. Parameters for tissue stress, such as mechanical phenotype index, correlate with cancer development and invasion [23]. Advancements in technology used for determining biophysical properties have facilitated the nano-level analysis of tumor tissues.
This study aims at investigating the correlation between TROP2 expression and clinicopathological characteristics of OSCC. We have demonstrated the tissue morphology and mechanics of OSCC samples during tumor development using AFM. We believe our findings will help develop TROP2 in accurately diagnosing OSCC in tumors with different grades of differentiation.

Methods

Tissue preparation

The protocols in this study were approved by the research ethics committee of Lanzhou University. Tumor samples were collected from patients after obtaining written informed consent. A total of 108 patients with oral squamous cell carcinoma (OSCC) were registered at the second hospital of Lanzhou University between January 2013 and March 2019. Among these samples, 36 samples each showed high, moderate, and low levels of differentiation. The experimental group comprised 60 males and 48 females aged 41–68 years (average: 51 years). All patients were diagnosed with OSCC based on surgery and pathology; patients did not undergo radiotherapy, chemotherapy, or immunotherapy before surgery. Pathological analysis after tumor biopsy was performed by two experienced pathologists, after which the diagnosis of other diseases (including inflammation at other sites and secondary tumors) were excluded. Cancer and cervical lymph node tissues were collected after maxillofacial surgery. All specimens were sampled from typical areas of the lesion and fixed with 10% neutral-buffered formalin followed by conventional paraffin embedding. Among them, 42 and 66 patients exhibited no and cervical lymph node metastases, respectively. Clinical TNM staging was performed according to the 7th edition TNM staging classification standard jointly developed by the International Union for Cancer Control and American Joint Committee on Cancer [24] and World Health Organization guidelines [25].

Hematoxylin and eosin (H&E) staining

OSCC tissues were fixed overnight using 10% neutral formalin (Solarbio, Beijing, China), paraffin embedded, sliced into 4-μm thick sections, dewaxed using xylene, and rehydrated using different concentrations of ethanol. The sections were stained with hematoxylin for 5 min and hydrochloric acid-ethanol and eosin for 3 min followed by gradient dehydration, transparentization, sealing, and neutral resin sealing (Solarbio, Beijing, China). Sections were visualized and imaged using the Olympus BX53 at magnifications of × 10, 20, and 40.

Immunohistochemistry

HE sections were subjected to the S-P method to detect TROP2 expression. The sections were incubated overnight with the primary antibody against TROP2 (1:1000, Abcam, USA) at 4 °C followed by incubation with biotin-labeled goat anti-rabbit IgG (1:5000, Abcam, USA) at 37 °C for 1 h. The sections were then developed using DAB (Beijing Zhongshan Golden Bridge Biotechnology, China), dehydrated, transparentization, and film and neutral resin sealed. The prepared sections were visualized using microscopy (Olympus BX53, Japan).

AFM

Fixed tissues were placed in Petri dishes containing phosphate-buffered saline. All analyses for mechanical properties were performed using the biological atomic force microscope (BioAFM; NanoWizard III, Bruker, USA). Silicon AFM probes from the Pointprobe® series with a force constant of 0.2 N/m (CONTR-reflex coating, NanoWorld, USA) were used. The spring constant of the probe was calibrated using built-in thermal vibration before measuring the resonance frequency of 13 kHz and thickness of 2 μm. AFM was performed using the contact model and a scan rate of 0.5 Hz/s in air. Force-distance curves are generated when the probe contacts the tissue following which, the structure, morphology, and mechanical properties of samples are measured at 5 μm/s [26]. Six random sites were selected for each sample and each site was measured 15 times. We used the modified Hertz contact model to analyze force-distance curves [27] and calculate Young’s modulus and roughness of OSCC tissues with varying differentiation.

Statistical analysis

Statistical analyses were performed using SPSS 22.0 (Statistical Product and Service Solutions, IBM). Force spectrum data were expressed as mean ± standard error and statistical comparisons were performed using one-way analysis of variance followed by the Tukey-Kramer HSD test for pair-wise comparisons. Pearson Chi-square test was used to analyze clinical features and TROP2 expression based on the calculated odds ratios (ORs) and 95% confidence interval (CI). Survival was evaluated using Kaplan-Meier curves and the difference was analyzed using the log-rank test. P < 0.05 was considered statistically significant.

Results

Tissue morphology and TROP2 expression across the clinical stages of OSCC

Tumor cells from poorly differentiated OSCC samples exhibited characteristic atypia, poor differentiation, and irregular morphology (Fig. 1). However, the number, volume, atypia, nuclear pyknosis, and mitotic structures decreased in tumor cells from highly differentiated OSCC as compared to those in poorly differentiated cells. TROP2 primarily localized in the cytoplasm of tumor cells, but not in adjacent normal epithelial cells. We observed that low differentiation and high malignancy of OSCC was associated with higher TROP2 expression (Fig. 2). The average optical density of TROP2 among the low, medium, and highly differentiated OSCC tissues were 0.32 ± 0.042, 0.25 ± 0.018, and 0.11 ± 0.013, respectively (Fig. 3).

Association between TROP2 expression and clinical characteristics of OSCC

We analyzed the clinicopathological characteristics of patients with OSCC with varying degree of differentiation. Differential expression of TROP2 was associated with patient age, tumor differentiation, tumor size, TNM stage, percutaneous nerve filtration, and vascular invasion (Table 1, P < 0.05). Patients with poorly differentiated tumors were more likely than patients with well and moderate differentiated tumors to have high TROP2 expression (P < 0.001). However, there was no association between the expression of TROP2 and patient gender, tumor location, lymph node metastasis, or distant metastases (P > 0.05).
Table 1
Correlation between TROP2 expression and clinicopathological characteristics
Characters
n
TROP2 expression(%)
Pearson  x2
P value
Low or no(%)
High(%)
Total
108
67
41
  
Gender
   
0.786
0.375
 Male
60
35
25
  
 Female
48
32
16
  
Age
   
4.254
0.039
  ≥ 50
61
43
18
  
 <50
47
24
23
  
Localization
   
2.217
0.136
 mucosa
21
16
5
  
 Tongue
87
51
36
  
Differentiation
   
77.268
< 0.001
 well
36
35
1
  
 Moderate
36
31
5
  
 Poor
36
2
34
  
Tumor size
   
32.883
< 0.001
 T1 ≤ 2 cm
59
51
8
  
 2 cm<T2 ≤ 4 cm
49
16
33
  
 T3>4cm
0
0
0
  
 T4b
0
0
0
  
Lymph node metastases
   
2.574
0.109
 N0
42
30
12
  
 NX
66
37
29
  
Distant metastases
   
1.015
0.314
 M0
70
41
29
  
 M1
38
26
12
  
TNM stage
   
67.880
< 0.001
 I + II
78
67
11
  
 III + IV
30
0
30
  
Perineural infiltration
   
16.881
< 0.001
 No
91
64
27
  
 Yes
17
3
14
  
Vascular invasion
   
27.688
< 0.001
 No
45
41
4
  
 Yes
63
26
37
  

TROP2 expression and patient survival

Using Kaplan-Meier survival curves, we observed that an increase in TROP2 expression negatively correlated with the overall survival of patients (Fig. 4). And low/no of TROP2 expression group’s 3-years survival rate was 55.6%, a 20.4% for high expression group and 5-years rate were 45.4 and 10.2% respectively. TROP2 expression was associated with patient age (P = 0.039, OR = 0.437, 95% CI [0.198–0.966]), tumor differentiation (Well vs. Moderate, P > 0.05, OR = 5.645, 95% CI [0.625–50.987]; Moderate vs. Poor, P < 0.001, OR = 105.400, 95% CI [19.053–583.063]; Well vs. Poor, P < 0.001, OR = 595.000, 95% CI [51.529–6870.366]), tumor size (P < 0.05, OR = 13.148, 95% CI [5.060–34.168]), TNM stage (P < 0.05, OR = 0.141, 95% CI [0.082–0.244]), vascular invasion (P < 0.05, OR = 14.587, 95% CI [4.653–45.729]), and peripheral nerve invasion (P < 0.05, OR = 11.062, Table 2). High TROP2 expression was detected in older patients with low degree of differentiation, larger tumor volume, higher TNM staging, and vascular and peripheral nerve invasion, thereby resulting in lower overall survival. Thus, TROP2 may be a prognostic indicator for survival in OSCC patients.
Table 2
TROP2 expression risk factors with clinicopathological features
Characteristics
n
TROP2 expression(%)
P value
OR (95% CI)
Low or no(%)
High(%)
Total
108
67
41
  
Gender
   
0.375
1.429 (0.649,3.147)
 Male
60
35
25
  
 Female
48
32
16
  
Age
   
0.039
0.437 (0.198,0.966)
  ≥ 50
61
43
18
  
 <50
47
24
23
  
Localization
   
0.136
0.443 (0.149,1.318)
 Mucosa
21
16
5
  
 Tongue
87
51
36
  
Differentiation
     
 Well
36
35
1
> 0.05a
5.645 (0.625,50.987)
 Moderate
36
31
5
< 0.001b
105.400 (19.053,583.063)
 Poor
36
2
34
< 0.001c
595.000 (51.529,6870.366)
Tumor size
   
< 0.001
13.148 (5.060,34.168)
 T1 ≤ 2 cm
59
51
8
  
 2 cm<T2 ≤ 4 cm
49
16
33
  
 T3>4cm
0
0
0
  
 T4b
0
0
0
  
Lymph node metastases
   
0.109
1.959 (0.857,4.482)
 N0
42
30
12
  
 NX
66
37
29
  
Distant metastases
   
0.314
0.653 (0.284,1.501)
 M0
70
41
29
  
 M1
38
26
12
  
TNM stage
   
< 0.001
0.141 (0.082,0.244)
 I + II
78
67
11
  
 III + IV
30
0
30
  
Perineural infiltration
   
< 0.001
11.062 (2.939,41.641)
 No
91
64
27
  
 Yes
17
3
14
  
Vscular invasion
   
< 0.001
14.587 (4.653,45.729)
 No
45
41
4
  
 Yes
63
26
37
  
Note: a, Well vs Moderate, b, Moderate vs Poor, c, Well vs Poor

Surface morphology and roughness of OSCC tissues

The surface morphologies of OSCC tissues with varying degrees of differentiation were analyzed (direct topographical imaging) using BioAFM. Figure 5 shows the representative image from each tissue acquired during the cantilever-based AFM nano- indentation test. The tissue interface varied with tumor differentiation, indicating that highly differentiated OSCC tissues had a regular and flat morphology. OSCC tissues with low differentiation exhibited an overall irregular morphology with distinct modulation and loose tissue organization. Figure 6 summarizes the roughness of OSCC tissues with varying differentiation. The average surface roughness of low, medium, and highly differentiated OSCC tissues were 448.9 ± 54.8, 792.7 ± 83.6, and 993.0 ± 104.3 nm, respectively. Roughness of the tissue surface was enhanced with increasing differentiation of OSCC tissues.

Young’s modulus of OSCC tissues

We used BioAFM to determine Young’s modulus based on the mechanical properties of 108 OSCC tissues with varying degrees of differentiation. We randomly selected six contact points from each slice and each contact point was measured 15 times. Force-distance curves were generated for each slice and the JPK Data Processing software (5.1.8 version) was used to calculate Young’s modulus. Figure 7 shows the average variation in stiffness within individual tissues in the range of 1–8 kPa. In the low differentiation samples, we observed low stiffness as compared to that in high or medium differentiation samples (P < 0.05). Thus, tissue differentiation was positively associated with its stiffness (Fig. 7).

Association between mechanical properties and TROP2 expression in OSCC

The Pearson coefficient showed a negative association between the stiffness of OSCC tissues and TROP2 expression (Fig. 8, r = − 0.84, P < 0.01). Thus, we detected an increase in stiffness with varying differentiation in the tumor samples.

Discussion

TROP2 belongs to the family of genes involved in calcium signaling associated with tumorigenesis and found in human trophoblast and chorionic cell lines. Studies have shown that overexpression of TROP2 is associated with tumorigenesis and malignancy [2830]. In this study, TROP2 expression was observed to be a highly sensitive and specific marker of tongue squamous cell carcinoma and tissue stiffness. The relative thickness of samples helped accurately diagnose and determine the staging of tongue squamous cell carcinoma.
Immunohistochemical analysis revealed that the expression of TROP2 in poorly differentiated OSCC tissues was significantly higher than that in well-differentiated OSCC tissues. Additionally, TROP2 upregulation was correlated with tumors of advanced TNM (III + IV) staging and poor differentiation than that in tumors with low TNM (I + II) staging. Thus, the abnormal expression of TROP2 may be associated with the occurrence and development of tongue malignancies. Furthermore, high TROP2 expression predicted low survival as compared to that in the tumors with low TROP2 expression. Previous research has also demonstrated the correlation between shorter patient lifespan and high levels of TROP2 as compared to that in patients with laryngeal squamous cell carcinoma and low levels of TROP2 [31]. TROP2 possesses sites for tyrosine/serine phosphorylation that regulate signal transduction or its expression and activity, thereby rendering cancer cells resistant to apoptosis [32]. Upregulated TROP2 correlates with the poor prognosis of thyroid papillary carcinoma [33], colon cancer [34], liver cancer [35], and other malignancies.
There have been an increasing number of studies on the biological role of TROP2 at the molecular level. TROP2 induces the downregulation/loss of PTEN, thereby stimulating PI3K/AKT signaling and tumor development [15]. PTEN is a well-known tumor suppressor that is a phosphatase [36] and affects the PI3K/PKB/AKT signaling axis during the dephosphorylation of PIP-2 and PIP-3 [37]. PI3K signaling is important in regulating tumor cell proliferation, migration, and invasion [38, 39]. Thus, PTEN is a negative regulator of cancer [40, 41]. Li et al. have shown that TROP2 activates epithelial-mesenchymal transition via PI3K/AKT signaling, thereby promoting proliferation, migration, and metastasis in gallbladder cancer [42]. Similarly, TROP2 expression stimulates the proliferation, migration, and invasion of osteosarcoma cells [43]. Hou et al. demonstrated that TROP2 regulates JAK2/STAT3 signaling in glioblastoma cells [44].
Functional differentiation of tissues influences the micro-morphology and mechanical stiffness of OSCC cells. We detected low surface roughness on OSCC tissues with loose structure, reduced hardness, and enhanced cell adhesion, migration, and invasion. Poorly differentiated OSCC tissues are “softer” than highly differentiated OSCC tissues. PI3K is an important cell-adhesion molecule. TROP2 triggers the synthesis of proteins with homologous domains, such as pleckstrin, RAC, Tiam, and Vav. Tiam and Vav activate RAC that leads to reorganization of the actin cytoskeleton, cell recognition, and adhesion [45].
The underlying mechanisms involved in the alteration of micromechanical properties of OSCC samples and occurrence, development, metastasis, and invasion of OSCC tumors remain to be elucidated. H&E staining is the gold standard for tumor diagnosis. With the development of biomechanics in the past two decades [46, 47], the mechanical properties of tissues need to be investigated based on biomedical and physical parameters. In this study, we have assayed the changes in mechanical properties at the micro-nanometer level using AFM and determined the association between the TNM grade, metastasis, and stiffness of tumor samples.
In conclusion, we have demonstrated the association between differential expression of TROP2 and patient age, tumor differentiation, tumor size, TNM stage, percutaneous nerve filtration, and vascular invasion. Moreover, high levels of TROP2 correlated with poor overall survival in patients. Highly differentiated cancer tissues exhibited increased surface roughness and stiffness. Lastly, high TROP2 expression resulted in reduced tumor stiffness. However, this study had some limitations. First, the cohort used in this study was relatively small. Second, we did not employ molecular methods of analysis such as western blotting or enzyme-linked immunosorbent assay. Thus, using a larger patient cohort and multiple techniques in molecular and cell biology will help validate our findings and develop TROP2 as a specific and efficient prognostic biomarker for OSCC.

Conclusion

These findings could promote new methods for the early OSCC diagnosis depend on the stage of cancer and developing screening methods with high sensitivity and specificity. More detailed studies are needed to determine the feasibility and therapeutic benefit of testing tissue stiffness in human disease.

Acknowledgements

We thank the individual who participated in this study.
Written informed consent was obtained from each participant before sample collection. The study was approved by the Committee for Ethical Affairs of School of Stomatology, Lanzhou University.
Not applicable.

Competing interests

The authors have no conflicts of interest.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Iyer S, Thankappan K, Balasubramanian D. Early detection of oral cancers: current status and future prospects. Curr Opin Otolaryngol Head Neck Surg. 2016;24(2):110–4.PubMed Iyer S, Thankappan K, Balasubramanian D. Early detection of oral cancers: current status and future prospects. Curr Opin Otolaryngol Head Neck Surg. 2016;24(2):110–4.PubMed
2.
Zurück zum Zitat Caldeira PC, Soto AML, de Aguiar MCF, Martins CC. Tumor depth of invasion and prognosis of early-stage oral squamous cell carcinoma: a meta-analysis. Oral Dis. 2019. Online ahead of print. Caldeira PC, Soto AML, de Aguiar MCF, Martins CC. Tumor depth of invasion and prognosis of early-stage oral squamous cell carcinoma: a meta-analysis. Oral Dis. 2019. Online ahead of print.
3.
Zurück zum Zitat Kim Y, Kim JH. Increasing incidence and improving survival of oral tongue squamous cell carcinoma. Sci Rep. 2020;10:7877.PubMedPubMedCentral Kim Y, Kim JH. Increasing incidence and improving survival of oral tongue squamous cell carcinoma. Sci Rep. 2020;10:7877.PubMedPubMedCentral
4.
Zurück zum Zitat McDougall AR, Tolcos M, Hooper SB, Cole TJ, Wallace MJ. Wallace. Trop2: from development to disease. Dev Dyn. 2015;244(2):99–109.PubMed McDougall AR, Tolcos M, Hooper SB, Cole TJ, Wallace MJ. Wallace. Trop2: from development to disease. Dev Dyn. 2015;244(2):99–109.PubMed
5.
Zurück zum Zitat Guan GF, Zhang DJ, Wen LJ, Yu DJ, Zhao Y, Zhu L, et al. Prognostic value of TROP2 in human nasopharyngeal carcinoma. Int J Clin Exp Pathol. 2015;8(9):10995–1004.PubMedPubMedCentral Guan GF, Zhang DJ, Wen LJ, Yu DJ, Zhao Y, Zhu L, et al. Prognostic value of TROP2 in human nasopharyngeal carcinoma. Int J Clin Exp Pathol. 2015;8(9):10995–1004.PubMedPubMedCentral
6.
Zurück zum Zitat Stewart D, Cristea M. Antibody-drug conjugates for ovarian cancer: current clinical development. Curr Opin Obstet Gynecol. 2019;31(1):18–23.PubMed Stewart D, Cristea M. Antibody-drug conjugates for ovarian cancer: current clinical development. Curr Opin Obstet Gynecol. 2019;31(1):18–23.PubMed
7.
Zurück zum Zitat Liu J, Yang D, Yin Z, Gao M, Tong H, Su Y, et al. A novel human monoclonal Trop2-IgG antibody inhibits ovarian cancer growth in vitro and in vivo. Biochem Biophys Res Commun. 2019;512(2):276–82.PubMed Liu J, Yang D, Yin Z, Gao M, Tong H, Su Y, et al. A novel human monoclonal Trop2-IgG antibody inhibits ovarian cancer growth in vitro and in vivo. Biochem Biophys Res Commun. 2019;512(2):276–82.PubMed
8.
Zurück zum Zitat Zhao W, Jia L, Kuai X, Tang Q, Huang X, Yang T, et al. The role and molecular mechanism of Trop2 induced epithelial-mesenchymal transition through mediated beta-catenin in gastric cancer. Cancer Med. 2019;8(3):1135–47.PubMedPubMedCentral Zhao W, Jia L, Kuai X, Tang Q, Huang X, Yang T, et al. The role and molecular mechanism of Trop2 induced epithelial-mesenchymal transition through mediated beta-catenin in gastric cancer. Cancer Med. 2019;8(3):1135–47.PubMedPubMedCentral
9.
Zurück zum Zitat Zhao W, Jia L, Zhang M, Huang X, Qian P, Tang Q, et al. The killing effect of novel bi-specific Trop2/PD-L1 CAR-T cell targeted gastric cancer. Am J Cancer Res. 2019;9(8):1846–56.PubMedPubMedCentral Zhao W, Jia L, Zhang M, Huang X, Qian P, Tang Q, et al. The killing effect of novel bi-specific Trop2/PD-L1 CAR-T cell targeted gastric cancer. Am J Cancer Res. 2019;9(8):1846–56.PubMedPubMedCentral
10.
Zurück zum Zitat Jordheim LP, Chettab K, Cros-Perrial E, Matera EL, Dumontet C. Unexpected growth-promoting effect of oxaliplatin in excision repair cross-complementation group 1 transfected human colon cancer cells. Pharmacology. 2018;102(3–4):161–8.PubMed Jordheim LP, Chettab K, Cros-Perrial E, Matera EL, Dumontet C. Unexpected growth-promoting effect of oxaliplatin in excision repair cross-complementation group 1 transfected human colon cancer cells. Pharmacology. 2018;102(3–4):161–8.PubMed
11.
Zurück zum Zitat Nishimura T, Mitsunaga M, Sawada R, Saruta M, Kobayashi H, Matsumoto N, et al. Photoimmunotherapy targeting biliary-pancreatic cancer with humanized anti-TROP2 antibody. Cancer Med. 2019;8(18):7781–92.PubMedPubMedCentral Nishimura T, Mitsunaga M, Sawada R, Saruta M, Kobayashi H, Matsumoto N, et al. Photoimmunotherapy targeting biliary-pancreatic cancer with humanized anti-TROP2 antibody. Cancer Med. 2019;8(18):7781–92.PubMedPubMedCentral
12.
Zurück zum Zitat Wang XD, Wang Q, Chen XL, Huang JF, Yin Y, Da P, et al. Trop2 inhibition suppresses the proliferation and invasion of laryngeal carcinoma cells via the extracellular signal-regulated kinase/mitogen-activated protein kinase pathway. Mol Med Rep. 2015;12(1):865–70.PubMedPubMedCentral Wang XD, Wang Q, Chen XL, Huang JF, Yin Y, Da P, et al. Trop2 inhibition suppresses the proliferation and invasion of laryngeal carcinoma cells via the extracellular signal-regulated kinase/mitogen-activated protein kinase pathway. Mol Med Rep. 2015;12(1):865–70.PubMedPubMedCentral
13.
Zurück zum Zitat Wanger TM, Dewitt S, Collins A, Maitland NJ, Poghosyan Z, Knauper V. Differential regulation of TROP2 release by PKC isoforms through vesicles and ADAM17. Cell Signal. 2015;27(7):1325–35.PubMed Wanger TM, Dewitt S, Collins A, Maitland NJ, Poghosyan Z, Knauper V. Differential regulation of TROP2 release by PKC isoforms through vesicles and ADAM17. Cell Signal. 2015;27(7):1325–35.PubMed
14.
Zurück zum Zitat Chen X, Pang B, Liang Y, Xu SC, Xin T, Fan HT, et al. Overexpression of EpCAM and Trop2 in pituitary adenomas. Int J Clin Exp Pathol. 2014;7(11):7907–14.PubMedPubMedCentral Chen X, Pang B, Liang Y, Xu SC, Xin T, Fan HT, et al. Overexpression of EpCAM and Trop2 in pituitary adenomas. Int J Clin Exp Pathol. 2014;7(11):7907–14.PubMedPubMedCentral
15.
Zurück zum Zitat Tang G, Tang Q, Jia L, Chen Y, Lin L, Kuai X, et al. TROP2 increases growth and metastasis of human oral squamous cell carcinoma through activation of the PI3K/Akt signaling pathway. Int J Mol Med. 2019;44(6):2161–70.PubMedPubMedCentral Tang G, Tang Q, Jia L, Chen Y, Lin L, Kuai X, et al. TROP2 increases growth and metastasis of human oral squamous cell carcinoma through activation of the PI3K/Akt signaling pathway. Int J Mol Med. 2019;44(6):2161–70.PubMedPubMedCentral
16.
Zurück zum Zitat Trerotola M, Li J, Alberti S, Languino LR. TROP2 inhibits prostate cancer cell adhesion to fibronectin through the β1 integrin-RACK1 axis. J Cell Physiol. 2012;227(11):3670–7.PubMedPubMedCentral Trerotola M, Li J, Alberti S, Languino LR. TROP2 inhibits prostate cancer cell adhesion to fibronectin through the β1 integrin-RACK1 axis. J Cell Physiol. 2012;227(11):3670–7.PubMedPubMedCentral
17.
Zurück zum Zitat Li T, Su Y, Yu X, Mouniir DSA, Masau JF, Wei X, et al. Trop2 guarantees cardioprotective effects of cortical bone-derived stem cells on myocardial ischemia/reperfusion injury. Cell Transplant. 2018;27(8):1256–68.PubMedPubMedCentral Li T, Su Y, Yu X, Mouniir DSA, Masau JF, Wei X, et al. Trop2 guarantees cardioprotective effects of cortical bone-derived stem cells on myocardial ischemia/reperfusion injury. Cell Transplant. 2018;27(8):1256–68.PubMedPubMedCentral
18.
Zurück zum Zitat Stoyanova T, Goldstein AS, Cai H, Drake JM, Huang J, Witte ON. Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via beta-catenin signaling. Genes Dev. 2012;26(20):2271–85.PubMedPubMedCentral Stoyanova T, Goldstein AS, Cai H, Drake JM, Huang J, Witte ON. Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via beta-catenin signaling. Genes Dev. 2012;26(20):2271–85.PubMedPubMedCentral
19.
Zurück zum Zitat Sun X, Xing G, Zhang C, Lu K, Wang Y, He X. Knockdown of Trop2 inhibits proliferation and migration and induces apoptosis of endometrial cancer cells via AKT/β-catenin pathway. Cell Biochem Funct. 2020. Sun X, Xing G, Zhang C, Lu K, Wang Y, He X. Knockdown of Trop2 inhibits proliferation and migration and induces apoptosis of endometrial cancer cells via AKT/β-catenin pathway. Cell Biochem Funct. 2020.
20.
Zurück zum Zitat Lee H, Jang Y, Seo J, Nam JM, Char K. Nanoparticle-functionalized polymer platform for controlling metastatic cancer cell adhesion, shape, and motility. ACS Nano. 2011;5(7):5444–56.PubMed Lee H, Jang Y, Seo J, Nam JM, Char K. Nanoparticle-functionalized polymer platform for controlling metastatic cancer cell adhesion, shape, and motility. ACS Nano. 2011;5(7):5444–56.PubMed
21.
Zurück zum Zitat Kruse SA, Smith JA, Lawrence AJ, Dresner MA, Manduca A, Greenleaf JF, et al. Tissue characterization using magnetic resonance elastography: preliminary results. Phys Med Biol. 2000;45(6):1579–90.PubMed Kruse SA, Smith JA, Lawrence AJ, Dresner MA, Manduca A, Greenleaf JF, et al. Tissue characterization using magnetic resonance elastography: preliminary results. Phys Med Biol. 2000;45(6):1579–90.PubMed
22.
Zurück zum Zitat Kaneko TS, Pejcic MR, Tehranzadeh J, Keyak JH. Relationships between material properties and CT scan data of cortical bone with and without metastatic lesions. Med Eng Phys. 2003;25(6):445–54.PubMed Kaneko TS, Pejcic MR, Tehranzadeh J, Keyak JH. Relationships between material properties and CT scan data of cortical bone with and without metastatic lesions. Med Eng Phys. 2003;25(6):445–54.PubMed
23.
Zurück zum Zitat Goetz JG, Minguet S, Navarro-Lerida I, Lazcano JJ, Samaniego R, Calvo E, et al. (2011) biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis. Cell. 2011;146:148–63.PubMedPubMedCentral Goetz JG, Minguet S, Navarro-Lerida I, Lazcano JJ, Samaniego R, Calvo E, et al. (2011) biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis. Cell. 2011;146:148–63.PubMedPubMedCentral
24.
Zurück zum Zitat Edge SB, Compton CC. Compton, the American joint committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–4.PubMed Edge SB, Compton CC. Compton, the American joint committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–4.PubMed
25.
Zurück zum Zitat Barnes L, Eveson JW, Reichart P, Sidransky D. Pathology & Genetics Head and Neck Tumours. Lyon: Barness; 2005. p. 254–6. Barnes L, Eveson JW, Reichart P, Sidransky D. Pathology & Genetics Head and Neck Tumours. Lyon: Barness; 2005. p. 254–6.
26.
Zurück zum Zitat Zhang B, Li L, Li Z, Liu Y, Zhang H, Wang J. Carbon ion-irradiated hepatoma cells exhibit coupling interplay between apoptotic signaling and morphological and mechanical remodeling. Sci Rep. 2016;6:35131.PubMedPubMedCentral Zhang B, Li L, Li Z, Liu Y, Zhang H, Wang J. Carbon ion-irradiated hepatoma cells exhibit coupling interplay between apoptotic signaling and morphological and mechanical remodeling. Sci Rep. 2016;6:35131.PubMedPubMedCentral
27.
Zurück zum Zitat Yan JF, Huang GY. A double-hertz model for adhesive contact between cylinders under inclined forces, Philos. Trans A Math Phys Eng Sci. 2019;475(2221):20180589. Yan JF, Huang GY. A double-hertz model for adhesive contact between cylinders under inclined forces, Philos. Trans A Math Phys Eng Sci. 2019;475(2221):20180589.
28.
Zurück zum Zitat Kowalsky CA, Faber MS, Nath A, Dann HE, Kelly VW, Liu L, et al. Rapid fine conformational epitope mapping using comprehensive mutagenesis and deep sequencing. J Biol Chem. 2015;290(44):26457–70.PubMedPubMedCentral Kowalsky CA, Faber MS, Nath A, Dann HE, Kelly VW, Liu L, et al. Rapid fine conformational epitope mapping using comprehensive mutagenesis and deep sequencing. J Biol Chem. 2015;290(44):26457–70.PubMedPubMedCentral
29.
Zurück zum Zitat Zeng P, Chen MB, Zhou LN, Tang M, Liu CY, Lu PH. Impact of TROP2 expression on prognosis in solid tumors: a systematic review and meta-analysis. Sci Rep. 2016;6:33658.PubMedPubMedCentral Zeng P, Chen MB, Zhou LN, Tang M, Liu CY, Lu PH. Impact of TROP2 expression on prognosis in solid tumors: a systematic review and meta-analysis. Sci Rep. 2016;6:33658.PubMedPubMedCentral
30.
Zurück zum Zitat Calvo A, Xiao N, Kang J, Best CJ, Leiva I, Emmert-Buck MR, et al. Alterations in gene expression profiles during prostate cancer progression: functional correlations to tumorigenicity and down-regulation of selenoprotein-P in mouse and human tumors. Cancer Res. 2012;62(18):5325–35. Calvo A, Xiao N, Kang J, Best CJ, Leiva I, Emmert-Buck MR, et al. Alterations in gene expression profiles during prostate cancer progression: functional correlations to tumorigenicity and down-regulation of selenoprotein-P in mouse and human tumors. Cancer Res. 2012;62(18):5325–35.
31.
Zurück zum Zitat Ju X, Jiao X, Ertel A, Casimiro MC, Di Sante G, Deng S, et al. V-Src oncogene induces Trop2 proteolytic activation via Cyclin D1. Cancer Res. 2016;76(22):6723–34.PubMedPubMedCentral Ju X, Jiao X, Ertel A, Casimiro MC, Di Sante G, Deng S, et al. V-Src oncogene induces Trop2 proteolytic activation via Cyclin D1. Cancer Res. 2016;76(22):6723–34.PubMedPubMedCentral
32.
Zurück zum Zitat Cubas R, Li M, Chen C, Yao Q. Trop2: a possible therapeutic target for late stage epithelial carcinomas. Biochim Biophys Acta. 2009;1796(2):309–14.PubMed Cubas R, Li M, Chen C, Yao Q. Trop2: a possible therapeutic target for late stage epithelial carcinomas. Biochim Biophys Acta. 2009;1796(2):309–14.PubMed
33.
Zurück zum Zitat Zargari N, Mokhtari M. Evaluation of diagnostic utility of immunohistochemistry markers of TROP2 and HBME-1 in the diagnosis of thyroid carcinoma. Eur Thyroid J. 2019;8:1–6.PubMed Zargari N, Mokhtari M. Evaluation of diagnostic utility of immunohistochemistry markers of TROP2 and HBME-1 in the diagnosis of thyroid carcinoma. Eur Thyroid J. 2019;8:1–6.PubMed
34.
Zurück zum Zitat Zhao P, Zhang Z. TNF-α promotes colon cancer cell migration and invasion by upregulating TROP2. Oncol Lett. 2018;15(3):3820–7.PubMedPubMedCentral Zhao P, Zhang Z. TNF-α promotes colon cancer cell migration and invasion by upregulating TROP2. Oncol Lett. 2018;15(3):3820–7.PubMedPubMedCentral
35.
Zurück zum Zitat Sin STK, Li Y, Liu M, Yuan YF, Ma S, Guan XY. Down-regulation of TROP-2 predicts poor prognosis of hepatocellular carcinoma patients. Hepatol Commun. 2018;2(11):1408–14.PubMedPubMedCentral Sin STK, Li Y, Liu M, Yuan YF, Ma S, Guan XY. Down-regulation of TROP-2 predicts poor prognosis of hepatocellular carcinoma patients. Hepatol Commun. 2018;2(11):1408–14.PubMedPubMedCentral
36.
Zurück zum Zitat Zhang Y, Zhang R, Luo G, Ai K. Long noncoding RNA SNHG1 promotes cell proliferation through PI3K/AKT signaling pathway in pancreatic ductal adenocarcinoma. J Cancer. 2018;9(15):2713–22.PubMedPubMedCentral Zhang Y, Zhang R, Luo G, Ai K. Long noncoding RNA SNHG1 promotes cell proliferation through PI3K/AKT signaling pathway in pancreatic ductal adenocarcinoma. J Cancer. 2018;9(15):2713–22.PubMedPubMedCentral
37.
Zurück zum Zitat Sai J, Owens P, Novitskiy SV, Hawkins OE, Vilgelm AE, Yang J, et al. PI3K inhibition reduces mammary tumor growth and facilitates antitumor immunity and anti-PD1 responses. Clin Cancer Res 24. 2017; 23(13):3371–3384. Sai J, Owens P, Novitskiy SV, Hawkins OE, Vilgelm AE, Yang J, et al. PI3K inhibition reduces mammary tumor growth and facilitates antitumor immunity and anti-PD1 responses. Clin Cancer Res 24. 2017; 23(13):3371–3384.
38.
Zurück zum Zitat Zhang XR, Wang SY, Sun W, Wei C. Isoliquiritigenin inhibits proliferation and metastasis of MKN28 gastric cancer cells by suppressing the PI3K/AKT/mTOR signaling pathway. Mol Med Rep. 2018;18(3):3429–36.PubMed Zhang XR, Wang SY, Sun W, Wei C. Isoliquiritigenin inhibits proliferation and metastasis of MKN28 gastric cancer cells by suppressing the PI3K/AKT/mTOR signaling pathway. Mol Med Rep. 2018;18(3):3429–36.PubMed
39.
Zurück zum Zitat Wise HM, Hermida MA, Leslie NR. Prostate cancer, PI3K, PTEN and prognosis. Clin Sci (Lond). 2017;131(3):197–210. Wise HM, Hermida MA, Leslie NR. Prostate cancer, PI3K, PTEN and prognosis. Clin Sci (Lond). 2017;131(3):197–210.
40.
Zurück zum Zitat Yuan B, Zou M, Zhao Y, Zhang K, Sun Y, Peng X. Up-regulation of miR-130b-3p activates the PTEN/PI3K/AKT/NF-κB pathway to defense against mycoplasma gallisepticum (HS Strain) infection of chicken. Int J Mol Sci. 2018; 19(8). pii: E2172. Yuan B, Zou M, Zhao Y, Zhang K, Sun Y, Peng X. Up-regulation of miR-130b-3p activates the PTEN/PI3K/AKT/NF-κB pathway to defense against mycoplasma gallisepticum (HS Strain) infection of chicken. Int J Mol Sci. 2018; 19(8). pii: E2172.
41.
Zurück zum Zitat Li JW, Wang XY, Zhang X, Gao L, Wang LF, Yin XH. Epicatechin protects against myocardial ischemiainduced cardiac injury via activation of the PTEN/PI3K/AKT pathway. Mol Med Rep. 2018;17(6):8300–8.PubMedPubMedCentral Li JW, Wang XY, Zhang X, Gao L, Wang LF, Yin XH. Epicatechin protects against myocardial ischemiainduced cardiac injury via activation of the PTEN/PI3K/AKT pathway. Mol Med Rep. 2018;17(6):8300–8.PubMedPubMedCentral
42.
Zurück zum Zitat Li X, Teng S, Zhang Y, Zhang W, Zhang X, Xu K, et al. TROP2 promotes proliferation, migration and metastasis of gallbladder cancer cells by regulating PI3K/AKT pathway and inducing EMT. Oncotarget. 2017;8(29):47052–63.PubMedPubMedCentral Li X, Teng S, Zhang Y, Zhang W, Zhang X, Xu K, et al. TROP2 promotes proliferation, migration and metastasis of gallbladder cancer cells by regulating PI3K/AKT pathway and inducing EMT. Oncotarget. 2017;8(29):47052–63.PubMedPubMedCentral
43.
Zurück zum Zitat Gu QZ, Nijiati A, Gao X, Tao KL, Li CD, Fan XP, et al. TROP2 promotes cell proliferation and migration in osteosarcoma through PI3K/AKT signaling. Mol Med Rep. 2018;18(2):1782–8.PubMed Gu QZ, Nijiati A, Gao X, Tao KL, Li CD, Fan XP, et al. TROP2 promotes cell proliferation and migration in osteosarcoma through PI3K/AKT signaling. Mol Med Rep. 2018;18(2):1782–8.PubMed
44.
Zurück zum Zitat Hou J, Lv A, Deng Q, Zhang G, Hu X, Cui H. TROP2 promotes the proliferation and metastasis of glioblastoma cells by activating the JAK2/STAT3 signaling pathway. Oncol Rep. 2019;41(2):753–64.PubMed Hou J, Lv A, Deng Q, Zhang G, Hu X, Cui H. TROP2 promotes the proliferation and metastasis of glioblastoma cells by activating the JAK2/STAT3 signaling pathway. Oncol Rep. 2019;41(2):753–64.PubMed
45.
Zurück zum Zitat Rivard N. Phosphatidylinositol 3-kinase: a key regulator in adherens junction formation and function. Front Biosci (Landmark Ed). 2009;14:510–22. Rivard N. Phosphatidylinositol 3-kinase: a key regulator in adherens junction formation and function. Front Biosci (Landmark Ed). 2009;14:510–22.
46.
Zurück zum Zitat Pankova D, Jiang Y, Chatzifrangkeskou M, Vendrell I, Buzzelli J, Ryan A, et al. RASSF1A controls tissue stiffness and cancer stem-like cells in lung adenocarcinoma. EMBO J. 2019;38(13):e100532.PubMedPubMedCentral Pankova D, Jiang Y, Chatzifrangkeskou M, Vendrell I, Buzzelli J, Ryan A, et al. RASSF1A controls tissue stiffness and cancer stem-like cells in lung adenocarcinoma. EMBO J. 2019;38(13):e100532.PubMedPubMedCentral
47.
Zurück zum Zitat Wullkopf L, West AV, Leijnse N, Cox TR, Madsen CD, Oddershede LB, et al. Cancer cells' ability to mechanically adjust to extracellular matrix stiffness correlates with their invasive potential. Mol Biol Cell. 2018;29(20):2378–85.PubMedPubMedCentral Wullkopf L, West AV, Leijnse N, Cox TR, Madsen CD, Oddershede LB, et al. Cancer cells' ability to mechanically adjust to extracellular matrix stiffness correlates with their invasive potential. Mol Biol Cell. 2018;29(20):2378–85.PubMedPubMedCentral
Metadaten
Titel
Tissue mechanics and expression of TROP2 in oral squamous cell carcinoma with varying differentiation
verfasst von
Baoping Zhang
Shuting Gao
Ruiping Li
Yiting Li
Rui Cao
Jingyang Cheng
Yumeng Guo
Errui Wang
Ying Huang
Kailiang Zhang
Publikationsdatum
01.12.2020
Verlag
BioMed Central
Erschienen in
BMC Cancer / Ausgabe 1/2020
Elektronische ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-020-07257-7

Weitere Artikel der Ausgabe 1/2020

BMC Cancer 1/2020 Zur Ausgabe

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.